MX2009002660A - Tratamiento de la esclerosis multiple (em) con campath 1h. - Google Patents

Tratamiento de la esclerosis multiple (em) con campath 1h.

Info

Publication number
MX2009002660A
MX2009002660A MX2009002660A MX2009002660A MX2009002660A MX 2009002660 A MX2009002660 A MX 2009002660A MX 2009002660 A MX2009002660 A MX 2009002660A MX 2009002660 A MX2009002660 A MX 2009002660A MX 2009002660 A MX2009002660 A MX 2009002660A
Authority
MX
Mexico
Prior art keywords
treatment
campath
multiple sclerosis
treatment cycle
cycle
Prior art date
Application number
MX2009002660A
Other languages
English (en)
Inventor
Andreas Sachse
David Harris Margolin
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38734000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009002660(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2009002660A publication Critical patent/MX2009002660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Método para el tratamiento de la esclerosis múltiple (EM) con Campath 1H con significativa eficacia y un favorable perfil de seguridad, que ofrece una aceptable relación beneficio/riesgo. Se describe especialmente el uso de Campath 1H (alemtuzumab) para la producción de un medicamento para el tratamiento de la esclerosis múltiple (EM), que comprende un primer ciclo de tratamiento seguido de al menos otro ciclo de tratamiento con Campath 1H (alemtuzumab), donde cada ciclo de tratamiento comprende 1-5 dosis diarias que se aplican en días consecutivos, donde la dosis diaria es>0 y =12 mg, y donde cada ciclo de tratamiento está separado del ciclo siguiente por al menos 1-24 meses. También se describen regímenes de tratamiento que comprenden la administración de menos de 12 mg/día de Campath 1H durante un período de 1-5 días consecutivos.
MX2009002660A 2006-09-13 2007-09-11 Tratamiento de la esclerosis multiple (em) con campath 1h. MX2009002660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84425106P 2006-09-13 2006-09-13
EP06090169 2006-09-14
PCT/EP2007/008084 WO2008031626A1 (en) 2006-09-13 2007-09-11 Treatment of multiple sclerosis (ms) with campath-1h

Publications (1)

Publication Number Publication Date
MX2009002660A true MX2009002660A (es) 2009-06-11

Family

ID=38734000

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013009511A MX354080B (es) 2006-09-13 2007-09-11 Tratamiento de la esclerosis multiple (em) con campath 1h.
MX2009002660A MX2009002660A (es) 2006-09-13 2007-09-11 Tratamiento de la esclerosis multiple (em) con campath 1h.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013009511A MX354080B (es) 2006-09-13 2007-09-11 Tratamiento de la esclerosis multiple (em) con campath 1h.

Country Status (22)

Country Link
EP (4) EP2444104A3 (es)
JP (6) JP5872756B2 (es)
KR (2) KR101583587B1 (es)
CN (1) CN102652832A (es)
AR (1) AR062779A1 (es)
BR (1) BRPI0716929A8 (es)
CA (1) CA2662531A1 (es)
CY (1) CY2016019I2 (es)
DK (1) DK2066352T3 (es)
ES (2) ES2917882T3 (es)
HK (1) HK1136773A1 (es)
HR (1) HRP20160211T1 (es)
HU (2) HUE026740T2 (es)
IL (3) IL197236A (es)
LT (1) LTC2066352I2 (es)
LU (1) LU93092I2 (es)
MX (2) MX354080B (es)
PL (2) PL2066352T3 (es)
PT (2) PT2066352E (es)
RS (1) RS54658B1 (es)
SI (1) SI2066352T1 (es)
WO (1) WO2008031626A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5872756B2 (ja) 2006-09-13 2016-03-01 アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト カンパス−１Ｈ（Ｃａｍｐａｔｈ−１Ｈ）による多発性硬化症（ＭＳ）治療
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
TW201825115A (zh) 2009-05-13 2018-07-16 美商建新公司 抗人類cd52免疫球蛋白
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
TW201841653A (zh) * 2017-04-21 2018-12-01 美商建新公司 以抗-cd52抗體治療多發性硬化症
US20220015500A1 (en) * 2018-12-12 2022-01-20 University Of Delaware Vibrational device and methods for mitigating symptoms of freezing of gait

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
JP5872756B2 (ja) 2006-09-13 2016-03-01 アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト カンパス−１Ｈ（Ｃａｍｐａｔｈ−１Ｈ）による多発性硬化症（ＭＳ）治療

Also Published As

Publication number Publication date
JP5872756B2 (ja) 2016-03-01
IL240394B (en) 2018-02-28
EP2066352A1 (en) 2009-06-10
AR062779A1 (es) 2008-12-03
JP2019167385A (ja) 2019-10-03
EP3028718B1 (en) 2022-03-23
EP2444104A3 (en) 2012-10-24
EP2433649A2 (en) 2012-03-28
PT2066352E (pt) 2016-03-31
JP2021107423A (ja) 2021-07-29
HRP20160211T1 (hr) 2016-03-25
CN102652832A (zh) 2012-09-05
JP2018024655A (ja) 2018-02-15
AU2007296857A1 (en) 2008-03-20
LU93092I2 (de) 2016-08-01
IL197236A0 (en) 2011-08-01
LTC2066352I2 (lt) 2017-09-25
ES2917882T3 (es) 2022-07-12
EP2066352B1 (en) 2015-12-02
SI2066352T1 (sl) 2016-05-31
IL257341A (en) 2018-03-29
KR20150039879A (ko) 2015-04-13
CA2662531A1 (en) 2008-03-20
HUE026740T2 (en) 2016-07-28
CY2016019I1 (el) 2016-10-05
EP2433649A3 (en) 2012-10-31
BRPI0716929A8 (pt) 2019-02-05
KR101583587B1 (ko) 2016-01-08
WO2008031626A1 (en) 2008-03-20
PL2066352T3 (pl) 2016-05-31
LTPA2016019I1 (lt) 2016-06-27
JP2010503631A (ja) 2010-02-04
RS54658B1 (en) 2016-08-31
PT3028718T (pt) 2022-06-09
BRPI0716929A2 (pt) 2013-09-17
DK2066352T3 (en) 2016-02-29
PL3028718T3 (pl) 2022-11-21
JP2016175929A (ja) 2016-10-06
CY2016019I2 (el) 2016-10-05
EP2444104A2 (en) 2012-04-25
EP3028718A1 (en) 2016-06-08
HUS1600028I1 (hu) 2016-07-28
ES2563068T3 (es) 2016-03-10
IL240394A0 (en) 2015-09-24
KR20090063215A (ko) 2009-06-17
JP6257287B2 (ja) 2018-01-10
MX354080B (es) 2018-02-12
JP2014058555A (ja) 2014-04-03
HK1136773A1 (en) 2010-07-09
IL197236A (en) 2015-08-31
RU2009113665A (ru) 2010-10-20

Similar Documents

Publication Publication Date Title
MX2009002660A (es) Tratamiento de la esclerosis multiple (em) con campath 1h.
CA2494234A1 (en) Methods and dosage forms for controlled delivery of paliperidone
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
PL1978912T3 (pl) Opakowanie dla produktów medycznych i podobnych
WO2005097076A3 (en) Low dose pharmaceutical products
WO2005117542A3 (en) Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
WO2018060463A3 (en) Treatment of prostate cancer
WO2007144169A3 (en) Entacapone-derivatives
PH12020551050A1 (en) G1t38 superior dosage regimes
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
TNSN07474A1 (en) Dosage regimen for prasugrel
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
TW200514582A (en) Transdermal preparation and method for reducing side effect in pergolide therapy
TW200724189A (en) Method of and system for predicting dose delivery
CY1117474T1 (el) Θεραπευτικη αγωγη της σκληρυνσης κατα πλακας (ms) me campath-1h
TH101417B (th) การรักษาโรคปลอกประสาทเสื่อมแข็ง (ms)
WO2006032053A3 (en) Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds
BR0311209A (pt) Método de produção de unidades de dosagem farmacêuticas para administração oral, uso de etonogestrel, e, tablete
WO2007067753A3 (en) Methods of reducing side effects in cancer therapy
TH101417A (th) การรักษาโรคปลอกประสาทเสื่อมแข็ง (ms)
RU2002126955A (ru) Способ лечения мастопатии
Kim et al. The Feasibility of High-Dose Dexamethasone (HD-DEX) in Idiopathic Thrombocytopenic Purpura (ITP) in Adults; a Multi-Center Study in Korea.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ALCAFLEU MANAGEMENT GMBH & CO. KG

FG Grant or registration